[go: up one dir, main page]

MX2009013950A - Combinaciones antitumorales que contienen un agente inhibidor de vegf e irinotecan. - Google Patents

Combinaciones antitumorales que contienen un agente inhibidor de vegf e irinotecan.

Info

Publication number
MX2009013950A
MX2009013950A MX2009013950A MX2009013950A MX2009013950A MX 2009013950 A MX2009013950 A MX 2009013950A MX 2009013950 A MX2009013950 A MX 2009013950A MX 2009013950 A MX2009013950 A MX 2009013950A MX 2009013950 A MX2009013950 A MX 2009013950A
Authority
MX
Mexico
Prior art keywords
irinotecan
inhibiting agent
combinations containing
antitumour
vegf inhibiting
Prior art date
Application number
MX2009013950A
Other languages
English (en)
Inventor
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Pascale Lejeune
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38961256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009013950(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MX2009013950A publication Critical patent/MX2009013950A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Combinaciones antitumorales constituidas por inhibidores de VEGF asociados con irinotecan útiles terapéuticamente en el tratamiento de enfermedades neoplásicas.
MX2009013950A 2007-07-05 2008-07-02 Combinaciones antitumorales que contienen un agente inhibidor de vegf e irinotecan. MX2009013950A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704868A FR2918279B1 (fr) 2007-07-05 2007-07-05 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
PCT/FR2008/000943 WO2009024667A2 (fr) 2007-07-05 2008-07-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan

Publications (1)

Publication Number Publication Date
MX2009013950A true MX2009013950A (es) 2010-03-09

Family

ID=38961256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013950A MX2009013950A (es) 2007-07-05 2008-07-02 Combinaciones antitumorales que contienen un agente inhibidor de vegf e irinotecan.

Country Status (24)

Country Link
US (3) US20100160233A1 (es)
EP (1) EP2173349B1 (es)
JP (4) JP2010532335A (es)
KR (4) KR20150048910A (es)
CN (3) CN101686975A (es)
AR (1) AR067420A1 (es)
AT (1) ATE500829T1 (es)
AU (1) AU2008290442B2 (es)
BR (1) BRPI0812835B8 (es)
CA (1) CA2693152C (es)
CY (1) CY1111675T1 (es)
DE (1) DE602008005457D1 (es)
DK (1) DK2173349T3 (es)
ES (1) ES2362637T3 (es)
FR (1) FR2918279B1 (es)
HR (1) HRP20110432T1 (es)
IL (2) IL203132A (es)
MX (1) MX2009013950A (es)
PL (1) PL2173349T3 (es)
PT (1) PT2173349E (es)
RS (1) RS51777B (es)
RU (1) RU2471483C2 (es)
SI (1) SI2173349T1 (es)
WO (1) WO2009024667A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
EP2344161B1 (en) * 2008-10-16 2018-12-19 Celator Pharmaceuticals, Inc. Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
US20130029909A1 (en) * 2009-09-15 2013-01-31 John Ryan Treatment of cancer
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
SI3170005T1 (sl) 2014-07-18 2019-08-30 Sanofi Postopek napovedovanja izida zdravljenja z afliberceptom, pacienta, pri katerem obstaja sum, da je zbolel za rakom
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
AU2003215594A1 (en) * 2002-03-01 2003-09-16 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050112061A1 (en) * 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives

Also Published As

Publication number Publication date
JP2019006785A (ja) 2019-01-17
PT2173349E (pt) 2011-06-02
WO2009024667A3 (fr) 2009-04-23
ATE500829T1 (de) 2011-03-15
BRPI0812835A2 (pt) 2014-12-09
FR2918279B1 (fr) 2010-10-22
EP2173349A2 (fr) 2010-04-14
US20140127202A1 (en) 2014-05-08
KR20150048910A (ko) 2015-05-07
RU2010103781A (ru) 2011-08-10
KR20180105261A (ko) 2018-09-27
AR067420A1 (es) 2009-10-07
FR2918279A1 (fr) 2009-01-09
CN103623392A (zh) 2014-03-12
HRP20110432T1 (hr) 2011-07-31
EP2173349B1 (fr) 2011-03-09
RS51777B (sr) 2011-12-31
IL240965A0 (en) 2015-10-29
CA2693152C (fr) 2019-02-26
US20190275147A1 (en) 2019-09-12
SI2173349T1 (sl) 2011-06-30
AU2008290442B2 (en) 2013-06-27
JP2017052789A (ja) 2017-03-16
AU2008290442A1 (en) 2009-02-26
DK2173349T3 (da) 2011-06-27
KR20100031123A (ko) 2010-03-19
DE602008005457D1 (de) 2011-04-21
JP2014240422A (ja) 2014-12-25
ES2362637T3 (es) 2011-07-08
RU2471483C2 (ru) 2013-01-10
IL203132A (en) 2015-09-24
KR20160079918A (ko) 2016-07-06
BRPI0812835B8 (pt) 2021-05-25
US20100160233A1 (en) 2010-06-24
CN105833244A (zh) 2016-08-10
CA2693152A1 (fr) 2009-02-26
CY1111675T1 (el) 2015-10-07
JP2010532335A (ja) 2010-10-07
BRPI0812835B1 (pt) 2020-09-08
CN101686975A (zh) 2010-03-31
PL2173349T3 (pl) 2011-08-31
WO2009024667A2 (fr) 2009-02-26

Similar Documents

Publication Publication Date Title
MX2009013950A (es) Combinaciones antitumorales que contienen un agente inhibidor de vegf e irinotecan.
IL201211A0 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
PL2601962T3 (pl) Schemat dawkowania LAG-3 do stosowania w leczeniu raka
ZA201202384B (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
GB2454118B (en) Hdac inhibitors and hormone targeted drugs for the treatment of cancer
ZA200908477B (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
SI2019104T1 (sl) Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
PT2254869T (pt) Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
WO2010077589A3 (en) Stat3 inhibitors and therapeutic methods using the same
IL206891A0 (en) Therapeutic inhibitors of pai-1 function and methods of their use
EP2012798A4 (en) USE OF INOSITOL-TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
PH12012501200A1 (en) Therapeutic combinations of theobromine and an antihistamine
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
GB201014391D0 (en) Drug composition and its use in therapy
JO2730B1 (en) Medications for the treatment of endometriosis
PH12012501369A1 (en) Drug combination with theobromine and its use in therapy
IL201426A (en) Drug combination and its use in the treatment of muscle loss
UA105940C2 (uk) Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю
PH12012501203A1 (en) Combination of theobromine with a decongestant and its use for the treatment of cough
EP1973398A4 (en) USE OF INOSITE TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
HK1166787A (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer

Legal Events

Date Code Title Description
FG Grant or registration